Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases1,2,3.
0.01EURAsk for quotation
Preț : Ask for quotation
Disponibil
Număr Catalog 421-82692-1CategorieAfaceri și industrie > Știință și laboratorFurnizorBPS BioscienceGentaurDimensiune1 mgTipsingle